A nationwide experiment is set to commence to aid individuals using appetite-suppressing injections in maintaining their weight loss. These injections have garnered widespread popularity globally, with over two million Britons using them, but concerns persist regarding weight regain.
Studies indicate that discontinuing the weekly injections often results in regaining lost fat without the recovery of muscle and bone mass. As a response, patients will be recruited from 94 general practitioner offices nationwide to evaluate the effectiveness of specialized fat jab clinics in sustaining weight loss.
Effective counseling and support are crucial for individuals to adopt significant dietary and lifestyle changes for enduring weight management. The limited capacity of the NHS to offer this support has led to the rationing of these drugs, compelling most users to purchase them privately.
The NHS will evaluate whether community-based support hubs can be a cost-efficient solution to facilitate the prescription of weight loss drugs. Users will undergo regular consultations focusing on assessing their nutritional well-being, physical performance, work involvement, and overall health.
Dr. Helen Parretti, the lead researcher from the University of East Anglia (UEA), proposed a novel care model centered on community-based support clinics. She emphasized the necessity of long-term follow-up care for individuals utilizing weekly injectable obesity management medications.
Prescription data reveals that 2.4 million individuals in the UK utilize potent appetite-suppressing drugs, with an additional 8% of the population contemplating their use. These medications mimic glucagon-like peptide 1 (GLP-1), regulating hunger and satiety and are now accessible in tablet form.
The introduction of Mounjaro in 2024 was met with enthusiasm, but subsequent investigations unveiled the rationing of these injections, limiting NHS access. This led to a phased rollout plan over a 12-year period, leaving a majority reliant on costly private prescriptions.
The upcoming trial, funded by the National Institute for Health and Care Research (NIHR), aims to enable the NHS to offer extensive support to prescribe these drugs to a larger populace. Prof. Olivia Wu, NIHR program director, emphasized the importance of continuous care to ensure sustained weight loss and improved health.
Commencing in 2028 with 1,000 participants, the randomized controlled trial will assess the effectiveness of the support hub in aiding individuals to maintain weight loss over a year. Dr. Parretti outlined that these hubs, staffed by trained primary care professionals and specialized weight-management teams, will offer personalized care and monitoring services.
Previous research by Oxford University highlighted the tendency for individuals to regain lost weight within a year of ceasing weight loss injections. The review of 11 studies involving 6,370 adults indicated an average weight loss of 8kg, with individuals reverting to their initial weight within 10 months post-treatment, suggesting potential lifelong drug dependency for many users.
A separate study by the University of Copenhagen revealed that nearly one-third of weight loss from injections comprises muscle and bone density loss. Discontinuation of GLP-1 drugs leads to fat reaccumulation while permanent muscle and bone mass reduction persists, complicating weight loss efforts and elevating risks of osteoporosis and frailty.
The collaborative trial led by UEA in partnership with several universities aims to address the challenges of sustaining weight loss post-injection therapy, providing a comprehensive care model for individuals grappling with obesity.
